Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03053128
Other study ID # 121-2016004
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 20, 2017
Est. completion date November 20, 2019

Study information

Verified date February 2020
Source Beijing Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Coronary heart disease (CHD) is a public health care challenge. There are three types of treatment for CHD, medication, percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG). However, some end-stage CHD patients lost the chance to get those treatment. Cardiac shock wave therapy (CSWT) is a new developed therapy for these patients, which is used in tens of countries all over the world. Safety, invasiveness, effectiveness is its advantage. Ischemia condition can be improved after CSWT. There are only three cities in China run the program of CSWT, which are Kunming, Beijing and Shanghai. The investigators designed a randomized double-blind study to evaluate the effectiveness and safety of CSWT.


Description:

Coronary heart disease (CHD) is a public health care challenge, which lead to 3.5 millions of people died in China every year. There are three types of treatment for CHD, medication, percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG). However, some end-stage CHD patients with severe cardiac ischemia lost the chance to get those treatment. Their quality of life is influenced by recurrent angina. Cardiac shock wave therapy (CSWT) is a new developed therapy for these patients, which is used in tens of countries all over the world. German and Japan are the countries earliest used CSWT. Safety, invasiveness, effectiveness is its advantage. Ischemia condition can be improved after CSWT by objective examination. New small vessels generation on ischemia area was found on mice and pig model. There are only three cities in China run the program of CSWT, that are Kunming, Beijing and Shanghai. Beijing hospital has the only CSWT machine in Beijing. The investigators designed a randomized double-blind study to evaluate the effectiveness and safety of CSWT.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date November 20, 2019
Est. primary completion date November 20, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria:

1. Multiple or diffused coronary artery stenosis by coronary angiography and not candidate for PCI or CABG;

2. Myocardial ischemia and/or cardiac dysfunction by objective exams;

3. Angina and/or heart failure could not be control after optimal medication treatment for coronary artery disease;

4. LVEF is above 30%;

5. Signed informed consent

Exclusion Criteria:

1. Acute myocardial infarction;

2. Within one month after PCI or CABG;

3. Heart transplant patient;

4. Mechanic valve implantation patient;

5. Uncontrolled heart failure with LVEF less than 30%;

6. Severe arrhythmia;

7. Pacemaker implantation patient;

8. Infective endocarditis;

9. Severe chronic obstructive pulmonary disease patient;

10. Pregnant or nursing patient;

11. Silicone breast forms patient;

12. Chest tumor patient;

13. Participant in other clinical trials at the same time.

Study Design


Intervention

Device:
Cardiac shock wave therapy
Patients in CSWT group will receive CSWT for a 3-month therapy, located in their ischemia area with a energy of 0.09mJ/mm2. Patients will get therapy on every first week of the month and rest for following three weeks.
Other:
Sham cardiac shock wave (Control group)
Patients in sham CSWT group will receive sham cardiac shock wave, which is segregated by an air cushion.

Locations

Country Name City State
China Beijing Hospital Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Beijing Hospital

Country where clinical trial is conducted

China, 

References & Publications (1)

Yu W, Shen T, Liu B, Wang S, Li J, Dai D, Cai J, He Q. Cardiac shock wave therapy attenuates H9c2 myoblast apoptosis by activating the AKT signal pathway. Cell Physiol Biochem. 2014;33(5):1293-303. doi: 10.1159/000358697. Epub 2014 Apr 28. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Myocardial perfusion score Myocardial perfusion score will be calculated by myocardial perfusion imaging though single-photon computer tomography. 1st week of fourth month from beginning of CSWT
Primary Ischemia area percentage Ischemia area will be calculated by myocardial perfusion imaging though single-photon computer tomography. 1st week of fourth month from beginning of CSWT
Secondary Cardiac wall motion amplitude Cardiac wall motion amplitude rate will be calculated by single-photon computer tomography. 1st week of fourth month from beginning of CSWT
Secondary Left ventricular thickness rate Left ventricular thickness rate will be calculated by single-photon computer tomography. 1st week of fourth month from beginning of CSWT
Secondary Cardiac enzyme Troponin T and troponin I will be tested at last time shock wave therapy of the first week. First week after CSWT
Secondary Angina score-SAQ SAQ angina score will be finished after three month of CSWT. 1st week of fourth month from beginning of CSWT
Secondary Quality of life (SF-36) SF-36 questionnaire will be used for QOL. 1st week of fourth month from beginning of CSWT
Secondary Six-minute of walk test 6MWT will be used for exertional capacity. 1st week of fourth month from beginning of CSWT
See also
  Status Clinical Trial Phase
Recruiting NCT06154473 - Assessment of Patients Undergoing Cardiac Surgery and Admitted to the Intensive Care Unit
Completed NCT03203057 - Induced Myocardial Ischemia: a Serial Troponin T and Troponin I Measurements N/A
Active, not recruiting NCT06235424 - Del Nido Versus HTK Cardioplegia in Adult Aortic Valve Replacement Phase 4
Completed NCT03859466 - Safety and Efficacy of Cardiac Shockwave Therapy in Patients Undergoing Coronary Artery Bypass Grafting N/A
Recruiting NCT04749212 - Perioperative Troponin I and NT Pro-BNP in Lung Resection
Recruiting NCT03798652 - Improved Prediction of Functional Recovery After Revascularisation Using Combined Assessment of Myocardial Ischaemia and Viability by CMR - Pilot Study
Recruiting NCT05726604 - 4D CT Scan Versus 3D CT Scan Concerning Cardiac Dosimetry Assesment for Left Sided Breast Cancers Radiotherapy N/A
Completed NCT04458155 - Li-Hep vs. Non-Li-Hep Coated Transfer Device
Not yet recruiting NCT06414330 - Ringer Acetate Based Modified Del Nido Cardioplegia Solution Versus HTK Solution Cardioplegia Solution in Cardiac Surgery N/A
Completed NCT02055443 - Myocardial Ischemia Detection for Early Identification of Patients With Ischemic Chest Pain N/A
Completed NCT03433963 - The Use of L-arginine to Mitigate the Cardiovascular Effects of Exposure to Traffic-related Air Pollution N/A
Recruiting NCT05757947 - Study of the No-touch Saphenous Vein Graft N/A
Completed NCT05164640 - Ischemia in Patients With Non-obstructive Disease (INOCA) in Italy INOCA IT Multicenter Registry" N/A
Completed NCT03642730 - Interactive Guided Ultrasound Examinations Done by Non-experts of Ultrasound Imaging N/A
Recruiting NCT05006183 - Instantaneous Wave-free Ratio Guidance Strategy Evaluation in the Treatment of Multivessel Acute Coronary Syndrome. N/A
Active, not recruiting NCT05453097 - Prognostic Value of the Selvester QRS Score for Perioperative Myocardial Injury Following Non-cardiac Surgery
Recruiting NCT03800082 - Development and Usability Testing of a Progressive WebApp for Women With Heart Disease N/A
Completed NCT03857503 - Radiographic Imaging Validation and EvALuation for Angio iFR (ReVEAL iFR)